Ovid Therapeutics Inc 8-K, filed Jun 10, 2022
Ovid Therapeutics Inc. (OVID)
About this 8-K
Ovid Therapeutics Inc filed this 8-K on June 10, 2022, reporting on events of June 9, 2022.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
Ovid Therapeutics Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on June 9, 2022. As of April 11, 2022, there were 70,417,345 shares of Company common stock outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 41,220,715 shares, or 58.53%, were present in person or represented by proxy, which constituted a quorum. Summarized below are descriptions of the proposals voted on at the Annual Meeting and the final results for each of the proposals. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022.
Proposal 1: The Company’s stockholders elected the nominees as directors to serve a three-year term until the 2025 Annual Meeting, or until their respective successors are duly elected and qualified, by the votes set forth in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominee |
|
For |
|
|
Withheld |
|
|
Broker Non-Votes |
|
|||
Kevin Fitzgerald |
|
23,339,939 |
|
|
|
76,303 |
|
|
|
17,804,473 |
|
|
Bart Friedman |
|
17,204,205 |
|
|
|
6,212,037 |
|
|
|
17,804,473 |
|
|
Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022 by the votes set forth in the table below:
|
|
|
|
|
For |
|
Against |
|
Abstain |
40,049,679 |
|
1,157,936 |
|
13,100 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OVID THERAPEUTICS INC. |
|
|
|
By: |
/s/ Thomas M. Perone |
|
Thomas M. Perone |
|
General Counsel & Corporate Secretary |
Dated: June 10, 2022